# FURLONG

Source: https://onco.cc/trials/furlong/  
OnCo record `furlong` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The head-to-head trial in which furmonertinib nearly doubled the time before lung cancer grew compared with gefitinib, mirroring FLAURA with a Chinese drug.

## Summary

358 patients, double blind. Median progression-free survival 20.8 versus 11.1 months (hazard ratio 0.44), with strong central nervous system activity and a tolerable safety profile. NMPA first-line approval June 2022. With AENEAS it gave China two domestic third-generation EGFR inhibitors competing with osimertinib on price after NRDL listing.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-10
- Tags: china
- Registry id: NCT03787992
- Phase: 3
- Setting: First-line EGFR-mutant (exon 19 deletion or L858R) locally advanced or metastatic NSCLC, China: furmonertinib vs gefitinib
- Sponsor: Shanghai Allist Pharmaceuticals
- Enrolled: 358
- Result: PFS 20.8 vs 11.1 months, HR 0.44.
- Outcomes: Progression-free survival: Furmonertinib 20.8 months vs Gefitinib 11.1 months, HR 0.44

## Sources

- ClinicalTrials.gov NCT03787992: https://clinicaltrials.gov/study/NCT03787992
- Lancet Respir Med 2022: https://doi.org/10.1016/S2213-2600(22)00168-0

## Connected records

- trials: [AENEAS](https://onco.cc/trials/aeneas/), [FLAURA2](https://onco.cc/trials/flaura2/)
- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Furmonertinib](https://onco.cc/drugs/furmonertinib/), [Gefitinib](https://onco.cc/drugs/gefitinib/)
- companies: [Shanghai Allist Pharmaceuticals](https://onco.cc/companies/allist/)
- institutions: [Shanghai Chest Hospital](https://onco.cc/institutions/shanghai-chest-hospital/)
- people: [Shun Lu](https://onco.cc/people/lu-shun/)
- key papers: [Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study](https://onco.cc/key-papers/paper-furlong-lancet-respir-med-2022/)

---
JSON: https://onco.cc/api/v1/entities/furlong.json